Gastroenterology

Gastroenterology

Volume 158, Issue 1, January 2020, Pages e3-e4
Gastroenterology

Electronic Clinical Challenges and Images in GI
An Unusual Case of Esophagitis

https://doi.org/10.1053/j.gastro.2019.07.024Get rights and content

Section snippets

Answer to: Image 2: Gastroesophageal Reflux Disease

Dabigatran is a novel, direct thrombin inhibitor (factor IIa) that is noninferior to warfarin in protecting patients from nonvalvular atrial fibrillation and in treating or preventing thromboembolic events.1 Gastroesophageal reflux disease is reportedly the most predominant nonbleeding adverse events in patients taking this medication.2 Although generally well-tolerated, as demonstrated in this case, a pill-induced esophagitis mediated by dabigatran can occur and is suggested to happen in as

References (3)

  • S.J. Connolly et al.

    Dabigatran versus warfarin in patients with atrial fibrillation

    N Engl J Med

    (2009)
There are more references available in the full text version of this article.

Cited by (3)

  • Drugs that affect blood coagulation, fibrinolysis and hemostasis

    2021, Side Effects of Drugs Annual
    Citation Excerpt :

    Computed tomography scanning revealed diffuse circumferential esophageal thickening and endoscopy showed a large, longitudinal area of mucosal sloughing in the middle-third of the esophagus. The authors attributed her diagnosis to dabigatran (Argueta et al., 2020) [A]. A case report described a case of chronic progressive immune hemolytic anemia attributed to dabigatran.

  • From Tartaric Acid to Grapes—An Unusual Form of Esophagitis

    2023, Journal fur Gastroenterologische und Hepatologische Erkrankungen

Conflicts of interest The authors disclose no conflicts.

View full text